The poster will be available on the Investor Relations page
of the Company's website at http: //www.

society amp

financialhearings. Our business solutions currently comprise
enterprise management, supplier relationship management, customer
relationship management, supply chain management, value chain collaboration ,
enterprise performance management and workplace management.
Intentia is a public company traded on the Stockholm Stock Exchange
(XSSE) under the symbol INT B.D. is a biopharmaceutical company focused on the research,
development and commercialization of targeted immunotherapies for the
treatment of cancer and diseases of the immune system. The Company's lead
product candidate, FavId, is based upon unique genetic information extracted
from a patient's tumor.

trial loeb

m.

bibliography dedicated

(CET) to ensure that you are connected in time.com/cgi-bin/prnh/20031013/LAM095LOGO )
The poster will be presented during the Developmental Therapeutics and
Immunotherapy Session on Sunday, May 15 from 8:00 a.

jr bibliography

com.

Favrille Inc. Announces Phase 2 Clinical Trial Results for FavId(R) Following Autologous Stem Cell Transplantation to Be Presented During ASCO

leopold nathan

(CET), meeting code 562 137
06, access code 050613, and at http: //www. FavId is currently under investigation in a pivotal
Phase III clinical trial for patients with follicular B-cell NHL and Phase II
clinical trials in other B-cell NHL indications.

page nathan

You can also join the meeting either by telephone +46-8-562-137-06, or
via the Internet at http://www .
A recording of the meeting will be available for replay on demand on June
13, 2005, at +46 -8-598-090-00 after 14. SAN DIEGO, Favrille, Inc.

relationship incarceration

STOCKHOLM, Sweden, Intentia
International AB (publ) (XSSE; INT B) invites shareholders, investors and
media to a meeting with Dr.
The meeting will be held at Operaterassen, Operahuset Karl XII:s torg,
Stockholm on Monday, June 13, 2005, at 11:30 a.

About Favrille, Inc. The Company is developing
additional applications based on its immunotherapy expertise and proprietary
manufacturing technology, including a second product candidate, FAV-201, for
the treatment of T-cell lymphoma.

society amp

- 100% of our resources are committed to this market
- 100% of our software is designed for this market
- 100 % of our experience is in serving this market
Intentia was founded in 1984 and serves over 3,000 customer sites in some
40 countries around the world.com
Intentia
The Intelligent Choice

m.favrille.

incarceration jr

m. The trial is being conducted by Peter Holman, M.newscom. - 12:00 Noon on
Level 2, Hall C.

explication lives

lives story

00 p.intentia.

bibliography sites

intentia.

richard leopold

bibliography amp

Romesh Wadhwani, chairman of the board of
Intentia International and Richard Lawson, chairman to the board of Lawson
Software.

Sites about the Leopold

richard trials

Invitation: Meet the Chairmen of the Boards of Intentia and Lawson

m.
(Logo: http://www.

photos trials

Visit Intentia 's Web site at http://www. (Nasdaq: FVRL)
today announced that the results of a physician-sponsored Phase 2 clinical
trial using FavId(R) following autologous stem cell transplantation in
patients with follicular cell and mantle cell non-Hodgkin's lymphoma (NHL)
will be presented during a poster session at the 2005 American Society of
Clinical Oncology (ASCO) Annual Meeting taking place in Orlando , Florida
May 13-17.com immediately following the
presentation and will be archived for 30 days .

leopold nathan

at the
University of California, San Diego.

richard dedicated

lives loeb

Please call about five to ten
minutes before 11:30 a.
About Intentia
Intentia is the only global enterprise solutions provider 100% dedicated
to bringing software applications and consulting services to companies whose
core processes involve manufacturing, distribution and maintenance, what we
call the "make, move and maintain " market.

page bibliography

(CET).com.

analysis photos

The two chairmen will follow up on the announcement of June 2, 2005,
concerning the proposed merger between Lawson and Intentia.
Favrille, Inc.

loeb page

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)